Andre Goy, MD, considers whether off-the-shelf CAR-T cell therapies are becoming a reality
Dr.
Dr. Goy on Future Agents in Lymphoma
Andre Goy
Andre Goy, MD, considers checkpoint inhibitors in hematologic malignancies
Dr.
Dr Andre Goy Discusses Potential Benefits of Earlier Use of CAR T Therapies
Andre Goy
Doctors Who Make a Difference | Dr. Andre Goy, M.D. | Oncologist
Discover Dr.
Dr. Andre Goy, MD speaks on precision medicine for the 4th Annual Precision Medicine Symposium
Update from program chair, Dr.
Dr. Andre Goy at "What's Next? How to get busy living!"
Dr.
Dr. Andre Goy on Future Treatments for Patients With Diffuse Large B-Cell Lymphoma
Andre Goy
Andre Goy, M.D., MS, leads a nationally recognized cancer center
Dr.
Dr. Goy on the Significance of Becoming an NCI-Designated Cancer Center
Andre Goy
Regional Cancer Care Center’s Dr. Andre Goy on the Challenges of Treating Hodgkin’s Lymphoma
Dr.
Dr. Andre Goy Discusses CAR-Modified T Cells in Lymphoma
Andre Goy
Andre Goy, MD, comments on the long-term outcome of acalabrutinib in MCL
Dr.
Andre Goy, MD, discusses the three-year survival analysis of the ZUMA-1 study from ASH 2019
Dr.
#UniteToPrevent - Andre Goy, MD
An interview with
Andre Goy, MD, explains how lenalidomide will impact the management of FL and MZL
Dr.
Dr. Goy on Future Treatment Approaches in MCL
Andre Goy
Dr. Goy on the Upcoming Conference at John Theurer Cancer Center
Andre Goy
Andre Goy, MD, on responses & outcomes when treating lymphoma with CAR-T therapies
Dr.
Dr. Goy Comments on Recent Developments in the Field of Immunology
Andre Goy
